The relationship of circulating insulin‐like growth factor 1, its binding protein‐3, prostate‐specific antigen and C‐reactive protein with disease stage in prostate cancer

Latif, ZA; McMillan, Donald C.; Wallace, Andrew M.; Sattar, Naveed; Mir, Khurrum; Jones, Gary E.; Underwood, Mark A.

doi:10.1046/j.1464-4096.2001.01641.x

Cited by 33 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IGF-I is a mitogen that regulates cell proliferation and also inhibits apoptosis (4). The bioavailability of IGF-I in the circulation and tissues is tightly regulated by IGF-binding proteins (IGFBP) that bind IGF-I with high affinity and specificity (5).…”

Section: Introductionmentioning

confidence: 99%

Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk: The Multiethnic Cohort

Cheng

Penney

Stram

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Collective evidence suggests that the insulin-like growth factor (IGF) system plays a role in prostate and breast cancer risk. IGF-binding proteins (IGFBP) are the principal regulatory molecules that modulate IGF-I bioavailability in the circulation and tissues. To examine whether inherited differences in the IGFBP1 and IGFBP3 genes influence prostate and breast cancer susceptibility, we conducted two large population-based association studies of African Americans, Native Hawaiians, Japanese Americans, Latinos, and Whites. To thoroughly assess the genetic variation across the two loci, we (a) sequenced the IGFBP1 and IGFBP3 exons in 95 aggressive prostate and 95 advanced breast cancer cases to ensure that we had identified all common missense variants and (b) characterized the linkage disequilibrium patterns and common haplotypes by genotyping 36 single nucleotide polymorphisms (SNP) spanning 71 kb across the loci (f20 kb upstream and f40 kb downstream, respectively) in a panel of 349 control subjects of the five racial/ethnic groups. No new missense SNPs were found. We identified three regions of strong linkage disequilibrium and selected a subset of 23 tagging SNPs that could accurately predict both the common IGFBP1 and IGFBP3 haplotypes and the remaining 13 SNPs. We tested the association between IGFBP1 and IGFBP3 genotypes and haplotypes for their associations with prostate and breast cancer risk in two large case-control studies nested within the Multiethnic Cohort [prostate cases/controls = 2,320/2,290; breast cases (largely postmenopausal)/controls = 1,615/1,962]. We observed no strong associations between IGFBP1 and IGFBP3 genotypes or haplotypes with either prostate or breast cancer risk. Our results suggest that common genetic variation in the IGFBP1 and IGFBP3 genes do not substantially influence prostate and breast cancer susceptibility. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1993 -7)

show abstract

Section: Introductionmentioning

confidence: 99%

Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk: The Multiethnic Cohort

Cheng

Penney

Stram

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…However, a growing body of evidence suggests that serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels may play a role in prostate cancer risk and/or severity (5,6). Previous findings relating circulating levels of IGF-1 and IGFBP-3 to prostate cancer risk and severity have been intriguing, although not entirely consistent (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Of note, a positive association between increased IGF-1 levels and prostate cancer was found in three prospective studies (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

IGF1 (CA)19 Repeat and IGFBP3 -202 A/C Genotypes and the Risk of Prostate Cancer in Black and White Men

Schildkraut

Demark‐Wahnefried²,

Wenham³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

We investigated the relationship between the insulin-like growth factor-1 (IGF1) cytosine-adenine repeat (CA) 19 polymorphism located upstream of the gene's transcription start site, the insulin-like growth factor binding protein-3 (IGFBP3) À202 A/C promoter region polymorphism, and prostate cancer risk in Black and White men. Study subjects were U.S. veterans ages 41 to 75 years identified at the Durham Veterans Administration Medical Center over a 2.5-year period. Controls (n = 93) were frequency matched to cases (n = 100) based on race (Black or White) and age. Multivariable unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for the associations between the polymorphisms and prostate cancer risk. For Blacks and Whites combined, an inverse association between prostate cancer and being homozygous for the most common IGF1 repeat allele, (CA) 19 , (adjusted OR, 0.3; 95% CI, 0.1-0.7) was observed. Similar associations were noted for both Blacks (OR, 0.2; 95% CI, 0.0-0.8) and Whites (OR, 0.4; 95% CI, 0.1-1.6) separately. No statistically significant associations between the IGFBP3 C allele and prostate cancer were noted for Blacks (adjusted OR, 2.3; 95% CI, 0.8-6.2) or Whites (OR, 1.0; 95% CI, 0.3-3.1).

show abstract

“…Hyperinsulinemia, which accompanies obesity the risk factor as insulin is simultaneously the tumor growth factor while insulin resistance is of importance in metabolic, hormonal, inflammatory, vascular disorders and cancer diseases [9][10][11][12].…”

Section: Resultsmentioning

confidence: 99%

Metabolic Abnormalities in Colorectal Cancer Patients

Zhukov¹

2013

AJNS

View full text Add to dashboard Cite

Abstract:Normally, cells grow, divide and produce more cells as they are needed to keep the body healthy and functioning properly. Cancer cell growth is different from normal cell growth. Instead of dying, cancer cells continue to grow and form new, abnormal cells. Aim of the research. The aim of the study was to estimate of the association between the anthropometric obesity, fasting serum concentration of glucose, glycosylated hemoglobin, insulin, total cholesterol, HDL/LDL fractions, triglycerides, a homeostasis model of assessment (HOMA-IR) colorectal cancer patients. Colon cancer was diagnosed in 239 patients aged from 35 to 76 years. For each patient, the following data were considered: anthropometric measurements (weight, height, waist circumference values), fasting serum concentration of glucose, glycosylated hemoglobin, insulin, total cholesterol, HDL/LDL fractions, triglycerides. Also, three index: BMI (Body Mass Index; kg/m2) HOMA-IR (Homeostasis Model of Assessment -Insulin Resistance; fasting glucose (mmol/L) x fasting insulin (mU/L)/22.5). The average fasting serum concentration of glucose, glycosylated hemoglobin, insulin, total cholesterol, HDL/LDL fractions, triglycerides and HOMA-IR index were statistically significantly higher in patients transverse colon cancer (P < 0.001). Triglycerides increased with the appropriate forms of CRC by 58.8%, 47%, 52.9% and 64.7%. Studies have shown a violation of the protein and lipid metabolism in patients with colon carcinogenesis, which should be assumed to prevail over anabolic processes.

show abstract

The relationship of circulating insulin‐like growth factor 1, its binding protein‐3, prostate‐specific antigen and C‐reactive protein with disease stage in prostate cancer

Abstract: Objective To assess the relationships among circulating insulin-like growth factor-1 (IGF- 1

Cited by 33 publications

References 16 publications

Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk: The Multiethnic Cohort

Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk: The Multiethnic Cohort

IGF1 (CA)19 Repeat and IGFBP3 -202 A/C Genotypes and the Risk of Prostate Cancer in Black and White Men

Metabolic Abnormalities in Colorectal Cancer Patients

Contact Info

Product

Resources

About